Oscar Palomares

List of Publications by Year in Descending Order

Source: https://exaly.com/author-pdf/9343582/oscar-palomares-publications-by-year.pdf

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

3,588 91 30 57 h-index g-index citations papers 7.6 4,774 5.29 97 avg, IF L-index ext. citations ext. papers

#	Paper	IF	Citations
91	COVID-19 vaccination in patients receiving allergen immunotherapy (AIT) or biologicals - EAACI recommendations <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2022 ,	9.3	1
90	EAACI Biologicals Guidelines-dupilumab for children and adults with moderate-to-severe atopic dermatitis. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2021 , 76, 988-1009	9.3	7
89	Allergoid-mannan conjugates imprint tolerogenic features in human macrophages. <i>Allergy:</i> European Journal of Allergy and Clinical Immunology, 2021 ,	9.3	1
88	The cannabinoid WIN55212-2 suppresses effector T-cell responses and promotes regulatory T cells in human tonsils. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2021 ,	9.3	O
87	The cannabinoid WIN55212-2 restores rhinovirus-induced epithelial barrier disruption. <i>Allergy:</i> European Journal of Allergy and Clinical Immunology, 2021 , 76, 1900-1902	9.3	3
86	Efficacy and safety of treatment with biologicals for severe chronic rhinosinusitis with nasal polyps: A systematic review for the EAACI guidelines. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2021 , 76, 2337-2353	9.3	23
85	One Hundred Ten Years of Allergen Immunotherapy: A Broad Look Into the Future. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2021 , 9, 1791-1803	5.4	5
84	Allergoid-mannan conjugates reprogram monocytes into tolerogenic dendritic cells via epigenetic and metabolic rewiring. <i>Journal of Allergy and Clinical Immunology</i> , 2021 ,	11.5	3
83	What is the contribution of IgE to nasal polyposis?. <i>Journal of Allergy and Clinical Immunology</i> , 2021 , 147, 1997-2008	11.5	9
82	Vaccines and allergic reactions: The past, the current COVID-19 pandemic, and future perspectives. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2021 , 76, 1640-1660	9.3	29
81	EAACI statement on the diagnosis, management and prevention of severe allergic reactions to COVID-19 vaccines. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2021 , 76, 1629-1639	9.3	54
80	Current perspective on eicosanoids in asthma and allergic diseases: EAACI Task Force consensus report, part I. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2021 , 76, 114-130	9.3	23
79	Biologicals in atopic disease in pregnancy: An EAACI position paper. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2021 , 76, 71-89	9.3	17
78	EAACI Biologicals Guidelines-Recommendations for severe asthma. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2021 , 76, 14-44	9.3	48
77	COVID-19 pandemic: Practical considerations on the organization of an allergy clinic-An EAACI/ARIA Position Paper. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2021 , 76, 648-676	9.3	46
76	Immune modulation via T regulatory cell enhancement: Disease-modifying therapies for autoimmunity and their potential for chronic allergic and inflammatory diseases-An EAACI position paper of the Task Force on Immunopharmacology (TIPCO). <i>Allergy: European Journal of Allergy and</i>	9.3	8
75	Efficacy and safety of dupilumab for moderate-to-severe atopic dermatitis: A systematic review for the EAACI biologicals guidelines. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2021 , 76, 45-58	9.3	17

(2020-2021)

74	Efficacy and safety of treatment with omalizumab for chronic spontaneous urticaria: A systematic review for the EAACI Biologicals Guidelines. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2021 , 76, 59-70	9.3	20
73	Omalizumab restores the ability of human plasmacytoid dendritic cells to induce Foxp3Tregs. <i>European Respiratory Journal</i> , 2021 , 57,	13.6	9
72	Persistent human bocavirus 1 infection and tonsillar immune responses. <i>Clinical and Translational Allergy</i> , 2021 , 11, e12030	5.2	1
71	COVID-19 pandemic and allergen immunotherapy-an EAACI survey. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2021 , 76, 3504-3516	9.3	16
70	Management of anaphylaxis due to COVID-19 vaccines in the elderly. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2021 , 76, 2952-2964	9.3	7
69	Cannabinoids induce functional Tregs by promoting tolerogenic DCs via autophagy and metabolic reprograming. <i>Mucosal Immunology</i> , 2021 ,	9.2	4
68	The Role of Cannabinoids in Allergic Diseases: Collegium Internationale Allergologicum (CIA) Update 2020. <i>International Archives of Allergy and Immunology</i> , 2020 , 181, 565-584	3.7	7
67	Considerations on biologicals for patients with allergic disease in times of the COVID-19 pandemic: An EAACI statement. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2020 , 75, 2764-2774	9.3	54
66	Efficacy and safety of treatment with dupilumab for severe asthma: A systematic review of the EAACI guidelines-Recommendations on the use of biologicals in severe asthma. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2020 , 75, 1058-1068	9.3	36
65	Immunology of COVID-19: Mechanisms, clinical outcome, diagnostics, and perspectives-A report of the European Academy of Allergy and Clinical Immunology (EAACI). <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2020 , 75, 2445-2476	9.3	81
64	Efficacy and safety of treatment with biologicals (benralizumab, dupilumab, mepolizumab, omalizumab and reslizumab) for severe eosinophilic asthma. A systematic review for the EAACI Guidelines - recommendations on the use of biologicals in severe asthma. <i>Allergy: European Journal</i>	9.3	90
63	Efficacy and safety of treatment with biologicals (benralizumab, dupilumab and omalizumab) for severe allergic asthma: A systematic review for the EAACI Guidelines - recommendations on the use of biologicals in severe asthma. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2020 ,	9.3	39
62	EAACI Research and Outreach Committee: Improving standards and facilitating global collaboration through a Research Excellence Network. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2020 , 75, 1899-1901	9.3	3
61	Use of biologicals in allergic and type-2 inflammatory diseases during the current COVID-19 pandemic: Position paper of Exteverband Deutscher Allergologen (AeDA), Deutsche Gesellschaft fEAllergologie und Klinische Immunologie (DGAKI), Gesellschaft fEPE iatrische Allergologie und	4.1	20
60	Alum impairs tolerogenic properties induced by allergoid-mannan conjugates inhibiting mTOR and metabolic reprogramming in human DCs. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2020 , 75, 648-659	9.3	21
59	State-of-the-art in marketed adjuvants and formulations in Allergen Immunotherapy: A position paper of the European Academy of Allergy and Clinical Immunology (EAACI). <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2020 , 75, 746-760	9.3	23
58	Allergic rhinitis. <i>Nature Reviews Disease Primers</i> , 2020 , 6, 95	51.1	85
57	Biologicals in allergic diseases and asthma: Toward personalized medicine and precision health: Highlights of the 3rd EAACI Master Class on Biologicals, San Lorenzo de El Escorial, Madrid, 2019. Allergy: Furgpean Journal of Allergy and Clinical Immunology, 2020, 75, 936-940.	9.3	7

56	Type 2 immunity in the skin and lungs. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2020 , 75, 1582-1605	9.3	111
55	In-vivo diagnostic test allergens in Europe: A call to action and proposal for recovery plan-An EAACI position paper. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2020 , 75, 2161-2169	9.3	14
54	A Combination of Polybacterial MV140 and V132 as a Potential Novel Trained Immunity-Based Vaccine for Genitourinary Tract Infections. <i>Frontiers in Immunology</i> , 2020 , 11, 612269	8.4	2
53	Prioritizing research challenges and funding for allergy and asthma and the need for translational research-The European Strategic Forum on Allergic Diseases. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2019 , 74, 2064-2076	9.3	25
52	EAACI Guidelines on Allergen Immunotherapy: House dust mite-driven allergic asthma. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2019 , 74, 855-873	9.3	96
51	IgE-Mediated Multimorbidities in Allergic Asthma and the Potential for Omalizumab Therapy. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2019 , 7, 1418-1429	5.4	40
50	Cystatin Prevents Development of Allergic Airway Inflammation in a Mouse Model. <i>Frontiers in Immunology</i> , 2019 , 10, 2280	8.4	14
49	Comparing biologicals and small molecule drug therapies for chronic respiratory diseases: An EAACI Taskforce on Immunopharmacology position paper. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2019 , 74, 432-448	9.3	23
48	A Fluorescent Probe to Unravel Functional Features of Cannabinoid Receptor CB in Human Blood and Tonsil Immune System Cells. <i>Bioconjugate Chemistry</i> , 2018 , 29, 382-389	6.3	16
47	Human CD40 ligand-expressing type 3 innate lymphoid cells induce IL-10-producing immature transitional regulatory B cells. <i>Journal of Allergy and Clinical Immunology</i> , 2018 , 142, 178-194.e11	11.5	35
46	Moving toward consensus on diagnosis and management of severe asthma in adults. <i>Current Medical Research and Opinion</i> , 2018 , 34, 387-399	2.5	7
45	Development of a Fluorescent Bodipy Probe for Visualization of the Serotonin 5-HT Receptor in Native Cells of the Immune System. <i>Bioconjugate Chemistry</i> , 2018 , 29, 2021-2027	6.3	12
44	Moving toward consensus on diagnosis and management of severe asthma in children. <i>Current Medical Research and Opinion</i> , 2018 , 34, 447-458	2.5	4
43	Human dendritic cells activated with MV130 induce Th1, Th17 and IL-10 responses via RIPK2 and MyD88 signalling pathways. <i>European Journal of Immunology</i> , 2018 , 48, 180-193	6.1	27
42	Novel vaccines targeting dendritic cells by coupling allergoids to mannan. <i>Allergo Journal</i> , 2018 , 27, 34	l-4 0	
41	Trained Immunity-Based Vaccines: A New Paradigm for the Development of Broad-Spectrum Anti-infectious Formulations. <i>Frontiers in Immunology</i> , 2018 , 9, 2936	8.4	109
40	The prostaglandin D receptor 2 pathway in asthma: a key player in airway inflammation. <i>Respiratory Research</i> , 2018 , 19, 189	7.3	46
39	Tonsillar cytokine expression between patients with tonsillar hypertrophy and recurrent tonsillitis. <i>Clinical and Translational Allergy</i> , 2018 , 8, 22	5.2	10

38	Novel vaccines targeting dendritic cells by coupling allergoids to mannan. <i>Allergo Journal International</i> , 2018 , 27, 256-262	1.5	21
37	Reply. Journal of Allergy and Clinical Immunology, 2017 , 139, 1405	11.5	1
36	Mite allergoids coupled to nonoxidized mannan from Saccharomyces cerevisae efficiently target canine dendritic cells for novel allergy immunotherapy in veterinary medicine. <i>Veterinary Immunology and Immunopathology</i> , 2017 , 190, 65-72	2	13
35	Mechanisms of immune regulation in allergic diseases: the role of regulatory T and B cells. <i>Immunological Reviews</i> , 2017 , 278, 219-236	11.3	140
34	divergEnt: How IgE Axis Contributes to the Continuum of Allergic Asthma and Anti-IgE Therapies. <i>International Journal of Molecular Sciences</i> , 2017 , 18,	6.3	24
33	The relationship of serum vitamins A, D, E and LL-37 levels with allergic status, tonsillar virus detection and immune response. <i>PLoS ONE</i> , 2017 , 12, e0172350	3.7	30
32	Immunology of the Asthmatic Response 2016 , 250-261.e5		1
31	Structural studies of novel glycoconjugates from polymerized allergens (allergoids) and mannans as allergy vaccines. <i>Glycoconjugate Journal</i> , 2016 , 33, 93-101	3	15
30	New Biological Insights in the Immunomodulatory Effects of Mucosal Polybacterial Vaccines in Clinical Practice. <i>Current Pharmaceutical Design</i> , 2016 , 22, 6283-6293	3.3	13
29	Novel vaccines targeting dendritic cells by coupling allergoids to nonoxidized mannan enhance allergen uptake and induce functional regulatory Trells through programmed death ligand 1. <i>Journal of Allergy and Clinical Immunology</i> , 2016 , 138, 558-567.e11	11.5	64
28	Act d 12 and Act d 13: two novel, masked, relevant allergens in kiwifruit seeds. <i>Journal of Allergy and Clinical Immunology</i> , 2014 , 133, 1765-7.e4	11.5	20
27	The expression of cannabinoid receptor 1 is significantly increased in atopic patients. <i>Journal of Allergy and Clinical Immunology</i> , 2014 , 133, 926-9.e2	11.5	15
26	Triggering of specific Toll-like receptors and proinflammatory cytokines breaks allergen-specific T-cell tolerance in human tonsils and peripheral blood. <i>Journal of Allergy and Clinical Immunology</i> , 2013 , 131, 875-85	11.5	69
25	Analysis of the structural and immunological stability of 2S albumin, nonspecific lipid transfer protein, and profilin allergens from mustard seeds. <i>Journal of Agricultural and Food Chemistry</i> , 2012 , 60, 6011-8	5.7	33
24	Induction and maintenance of allergen-specific FOXP3+ Treg cells in human tonsils as potential first-line organs of oral tolerance. <i>Journal of Allergy and Clinical Immunology</i> , 2012 , 129, 510-20, 520.e1	-9 ^{11.5}	118
23	TH17 and TH22 cells: a confusion of antimicrobial response with tissue inflammation versus protection. <i>Journal of Allergy and Clinical Immunology</i> , 2012 , 129, 1438-49; quiz1450-1	11.5	131
22	The 11S globulin Sin a 2 from yellow mustard seeds shows IgE cross-reactivity with homologous counterparts from tree nuts and peanut. <i>Clinical and Translational Allergy</i> , 2012 , 2, 23	5.2	19
21	Chemical Probes for the Recognition of Cannabinoid Receptors in Native Systems. <i>Angewandte Chemie</i> , 2012 , 124, 7002-7005	3.6	3

20	Chemical probes for the recognition of cannabinoid receptors in native systems. <i>Angewandte Chemie - International Edition</i> , 2012 , 51, 6896-9	16.4	26
19	Interleukins, from 1 to 37, and interferon-Ereceptors, functions, and roles in diseases. <i>Journal of Allergy and Clinical Immunology</i> , 2011 , 127, 701-21.e1-70	11.5	512
18	Improvement of mustard (Sinapis alba) allergy diagnosis and management by linking clinical features and component-resolved approaches. <i>Journal of Allergy and Clinical Immunology</i> , 2011 , 127, 1304-7	11.5	27
17	The many routes of dendritic cells to ensure immune regulation. <i>Journal of Allergy and Clinical Immunology</i> , 2011 , 127, 1541-2	11.5	12
16	Role of Treg in immune regulation of allergic diseases. <i>European Journal of Immunology</i> , 2010 , 40, 1232-	- 4 01	278
15	Transcription factors RUNX1 and RUNX3 in the induction and suppressive function of Foxp3+ inducible regulatory T cells. <i>Journal of Experimental Medicine</i> , 2009 , 206, 2701-15	16.6	170
14	Airway disease and thaumatin-like protein in an olive-oil mill worker. <i>New England Journal of Medicine</i> , 2008 , 358, 1306-8	59.2	26
13	Solution structure of the C-terminal domain of Ole e 9, a major allergen of olive pollen. <i>Protein Science</i> , 2008 , 17, 371-6	6.3	23
12	Cloning, sequencing, and recombinant production of Sin a 2, an allergenic 11S globulin from yellow mustard seeds. <i>Journal of Allergy and Clinical Immunology</i> , 2007 , 119, 1189-96	11.5	24
11	Emerging pollen allergens. Biomedicine and Pharmacotherapy, 2007, 61, 1-7	7.5	17
10	Variability of Ole e 9 allergen in olive pollen extracts: relevance of minor allergens in immunotherapy treatments. <i>International Archives of Allergy and Immunology</i> , 2006 , 140, 131-8	3.7	26
9	Hypersensitivity to black locust (Robinia pseudoacacia) pollen: "allergy mirages". <i>Annals of Allergy, Asthma and Immunology,</i> 2006 , 96, 586-92	3.2	13
8	The major allergen of olive pollen Ole e 1 is a diagnostic marker for sensitization to Oleaceae. <i>International Archives of Allergy and Immunology</i> , 2006 , 141, 110-8	3.7	59
7	Allergenic contribution of the IgE-reactive domains of the 1,3-beta-glucanase Ole e 9: diagnostic value in olive pollen allergy. <i>Annals of Allergy, Asthma and Immunology</i> , 2006 , 97, 61-5	3.2	18
6	Isolation and identification of an 11S globulin as a new major allergen in mustard seeds. <i>Annals of Allergy, Asthma and Immunology</i> , 2005 , 94, 586-92	3.2	47
5	A recombinant precursor of the mustard allergen Sin a 1 retains the biochemical and immunological features of the heterodimeric native protein. <i>International Archives of Allergy and Immunology</i> , 2005 , 137, 18-26	3.7	20
4	A major allergen from pollen defines a novel family of plant proteins and shows intra- and interspecies [correction of interspecie] cross-reactivity. <i>Journal of Immunology</i> , 2004 , 172, 3644-51	5.3	55
3	Solution structure and stability against digestion of rproBnIb, a recombinant 2S albumin from rapeseed: relationship to its allergenic properties. <i>Biochemistry</i> , 2004 , 43, 16036-45	3.2	38

LIST OF PUBLICATIONS

The C-terminal segment of the 1,3-beta-glucanase Ole e 9 from olive (Olea europaea) pollen is an independent domain with allergenic activity: expression in Pichia pastoris and characterization.

Biochemical Journal, 2003, 369, 593-601

3.8 31

Recombinant pronapin precursor produced in Pichia pastoris displays structural and immunologic equivalent properties to its mature product isolated from rapeseed. *FEBS Journal*, **2002**, 269, 2538-45

16